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ORIGINAL ARTICLEMultiple Sclerosis
Improved Detection of Active Cerebral Lesions With 3-Dimensional T1
Black-Blood Magnetic Resonance Imaging Compared With Conventional
3-Dimensional T1 GRE ImagingNora N. Sommer, MD,* Tobias Saam, MD,*† Eva Coppenrath, MD,* Hendrik Kooijman, PhD,‡
Tania Kümpfel, MD,§ Maximilian Patzig, MD,|| Sebastian E. Beyer, MD,* Wieland H. Sommer, MD,*
Maximilian F. Reiser, MD,* Birgit Ertl-Wagner, MD,* and Karla M. Treitl, MD*¶Objectives: The aim of this study was to assess the diagnostic accuracy of a
modified high-resolution whole-brain three-dimensional T1-weighted black-
blood sequence (T1-weighted modified volumetric isotropic turbo spin echo
acquisition [T1-mVISTA]) in comparison to a standard three-dimensional
T1-weighted magnetization-prepared rapid gradient echo (MP-RAGE) sequence
for detection of contrast-enhancing cerebral lesions in patients with relapsing-
remitting multiple sclerosis (MS).
Materials andMethods:After institutional review board approval and informed
consent, 22 patients (8 men; aged 31.0 ± 9.2 years) with relapsing-remitting MS
were included in this monocentric prospective cohort study.
Contrast-enhanced T1-mVISTA and MP-RAGE, both with 0.8 mm3 resolution,
were performed in all patients. In a substudy of 12 patients, T1-mVISTAwas compared
with aT1-mVISTAwith 1.0mm3 resolution (T1-mVISTA_1.0). Reference lesionswere
defined by an experienced neuroradiologist using all available sequences and
served as the criterion standard. T1-mVISTA, T1-mVISTA_1.0, and MP-RAGE
sequences were read in random order 4 weeks apart. Image quality, visual contrast
enhancement, contrast-to-noise-ratio (CNR), diagnostic confidence, and lesion
size were assessed and compared by Wilcoxon and Mann-Whitney U tests.
Results: Eleven of 22 patients displayed contrast-enhancing lesions. Visual con-
trast enhancement, CNR, and diagnostic confidence of contrast-enhancing MS
lesions were significantly increased in T1-mVISTA compared with MP-RAGE
(P < 0.001). Significantly more contrast-enhancing lesions were detected with
T1-mVISTA than with MP-RAGE (71 vs 39, respectively; P < 0.001). With
MP-RAGE, 25.6% of lesions were missed in the initial reading, whereas only
4.2% of lesions were missed with T1-mVISTA. Increase of the voxel volume
from 0.8 mm to 1.0 mm isotropic in T1-mVISTA_1.0 did not affect the detect-
ability of lesions, whereas scan time was decreased from 4:43 to 1:55 minutes.
Conclusions: Three-dimensional T1-mVISTA improves the detection rates of
contrast-enhancing cerebral MS lesions compared with conventional 3D
MP-RAGE sequences by increasing CNR of lesions and might, therefore, be use-
ful in patient management.
Key Words: 3D black-blood imaging, high resolution, whole brain,
T1-mVISTA, MP-RAGE, multiple sclerosis, cerebral lesions, MRI
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Copyright © 2017 Wolters Kluwer HC ontrast-enhanced magnetic resonance imaging (MRI) is currentlythe criterion standard for the detection of active lesions in patients
withmultiple sclerosis (MS) and is necessary for diagnosis according to
the revised McDonald and the MAGNIMS consensus guidelines.1,2
Moreover, contrast-enhanced MRI has been shown to display higher
disease activity than suspected by clinical symptoms and is recom-
mended for follow-up and monitoring in clinical studies.3
Three-dimensional (3D) T1-weighted (T1w)magnetization-prepared
rapid gradient echo sequences (MP-RAGE) are widely used in standard
clinical protocols when using contrast-enhanced MRI. However, al-
though precontrast MP-RAGE is widely accepted for anatomical studies
and gray and white matter imaging, the choice of the postgadolinium
T1w is much more debated: T1w 2-dimensional (2D) spin echo (SE)
sequences are recommended for detection of active lesions3,4 and 3D
steady-state spoiled gradient recalled echo sequences (fast angle low
shot; FLASH) have been suggested as an option in MS protocols.4,5
In general, postcontrast 2D SE sequences are known to provide
an increased signal-to-noise ratio compared with 3D GRE sequences
such asMP-RAGE or FLASH6–9 and superior detection rates have been
reported on 2D SE compared with 3D GRE.9,10 On the other hand, other
studies reported increased detection rates in 3D GRE sequences as result
of a decrease of the partial volume effect due to higher resolution, thin-
ner slices, and the option of multiplanar image reconstruction.6,11
Nevertheless, all conventional protocols show only a slight to
moderate correlation to clinical manifestations and have limited prog-
nostic value to predict progression of disease.1,12,13 Indeed, earlier diag-
nosis, especially in patients with clinically isolated syndrome, can affect
therapeutic concepts and might improve long-term outcomes13,14 be-
cause disease activity predicts long-term disability.14
Therefore, investigation of new imaging strategies seems to
be appropriate.
Until recently, the use of 3D T1w turbo spin echo (TSE) se-
quences was restricted by reaching the limits of the specific absorption
rate due to long echo trains combined with short repetition times and as-
sociated high levels of radio frequency energy applied. New MRI tech-
niques, such as parallel imaging techniques, allow significant reduction
of acquisition times.15,16 In addition, the use of variable refocusing an-
gles allows a further decrease of acquisition time and specific absorp-
tion rate, whereas image resolution can be increased.17,18
Initial studies in patients with intracranial metastases have shown
that the use of 3D T1w TSE sequences with variable refocusing angles
lead to a significant increase in signal intensity of lesions through a sig-
nificant increase of the contrast-to-noise ratio (CNR), thus, leading to a
superior detectability of lesions.19,20 Moreover, black-blood (BB) con-
trast was reported to be supportive for detection of contrast-enhancing
brain metastasis, as distracting signal from blood vessels is sup-
pressed.21,22 However, up to now, BB suppression was only achievable
by using double inversion recovery resulting in small 2D stacks of a few
centimeter23 or in 3D sequences by using a motion-sensitized driven
equilibrium prepulse, which suffers from decreased T1 contrast, as itwww.investigativeradiology.com 13
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TSE BB sequence with variable refocusing flip angles sweeps (T1-weighted
modified volumetric isotropic TSE acquisition [T1-mVISTA]).25 This
sequence provides a submillimeter isotropic resolution, coverage of
the whole brain, reconstruction in all planes, and scan times under
5 minutes. In an initial study in patients with cerebral metastases, detec-
tion rates with T1-mVISTAwere nearly doubled, especially in small le-
sions under 5 mm.25
The aim of this study, therefore, was to evaluate the accuracy of a
contrast-enhanced 3D T1-mVISTA in comparison to the standard
contrast-enhanced 3D MP-RAGE sequence for the detection of active
cerebral lesions in patients with relapsing-remitting MS (RRMS).
MATERIALS AND METHODS
Study Design and Study Population
The study was designed as a prospective monocentric cohort
study and followed the principles of the Declaration of Helsinki. Ap-
proval by the institutional review boardwas given, andwritten informed
consent was obtained from all patients. Patients were recruited between
October 2013 and January 2016.
Inclusion Criteria
Patients with RRMS diagnosed by an experienced neurologist
according to the McDonald criteria were included.
Exclusion Criteria
Patients with (a) vasculitis, (b) a tumor, (c) stroke, and (d) typical
MR contraindications as well as (e) RRMS patients with corticosteroid
therapy within the last 4 weeks were excluded.
MRI Protocol
Scans were performed on a 3 T scanner (Ingenia; Philips Health-
care, Best, the Netherlands) using a commercial 8-channel head coil.
All patients underwent MRI for clinical reasons.TABLE 1. MR Parameters
T1-mVISTA




SENSE factor (A/P, R/L) 1.7/2.5
TFE factor NA
Echo spacing/ETL 4.0/243
Flip angle, degrees Variable
NSA 2
Scan FOV, mm3 200  251  160
Recon matrix 267  335
No. slices 427
Voxel size, mm3 0.75  0.75  0.75
Recon voxel size, mm3 0.39  0.39  0.35
Scan time, min 4:43
Flow compensation No
Slice orientation Sagittal
A/P indicates anterior posterior; ETL, echo train length; FOV, field of view; GE, gra
plicable; NSA, number of signal averages; R/L, right left; SPIR, spectral presaturation
field echo; TR, repetition time; TSE, turbo spin echo; T1w, T1-weighted; T1-mVISTA
T1-weighted modified volumetric isotropic TSE acquisition with 1.0 mm3 resolution;
14 www.investigativeradiology.com
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fluid attenuation inversion recovery (FLAIR; repetition time [TR], 4800;
echo time [TE], 335; TI, 1650; matrix, 224  224), axial T2w TSE
(TR, 3965; TE, 80; matrix, 420  270), diffusion-weighted imaging
(TR, 3690; TE, 63; matrix, 152  129), and nonenhanced and
contrast-enhanced T1-mVISTA and MP-RAGE sequences, both with
0.8 mm3 resolution. We additionally performed a contrast-enhanced
T1-mVISTAwith 1.0 mm3 resolution (T1-mVISTA_1.0) in a subgroup
of the cohort for analysis of the acquisition time and image quality of
T1-mVISTA_1.0 as a proof of concept. Detailed scan parameters for
T1-mVISTA and MP-RAGE are listed in Table 1. To increase the
signal-to-noise ratio, all images were reconstructed with a slice thick-
ness of 1.5 mm.
The field of view covered thewhole brain, reaching from the ver-
tex to the medulla oblongata. An amount of 0.2 mL/kg body weight of
gadoteric acid (DOTAREM 0.5 mmol/mL; Guerbet, Roissy, France)
was administered. The first postcontrast scan was started 4 minutes af-
ter injection.26 Contrast-enhanced MP-RAGE and T1-mVISTA were
acquired in alternating random order to prevent bias due to the potential
increase of contrast agent uptake by increased time after injection.27
Definition of Criterion Standard
Our criterion standard was based on predefined reference le-
sions, which were assessed by reading all available sequences by an ex-
perienced neuroradiologist, who did not act as a reader. A contrast-
enhancing MS lesion was defined as a focal enhancement on the
postcontrast image corresponding to a T2 FLAIR hyperintensity. Im-
ages were provided in axial, sagittal, and coronar reformation.
Image Analysis
The first reader, with more than 15 years of experience, analyzed
contrast-enhanced T1-mVISTA, T1-mVISTA_1.0, and MP-RAGE se-
quences in a random order 4 weeks apart. Sequences were provided
in axial, sagittal, and coronal planes with a reconstructed slice thickness
of 1.5mm. Three-dimensional T2wFLAIR images and the correspondingT1-mVISTA_1.0 MP-RAGE









200  251  160 240  250  190
200  251 300  312
320 476
1.0  1.0  1.0 0.8  0.8  0.8




dient echo; MP-RAGE, magnetization-prepared rapid gradient echo; NA, not ap-
with inversion recovery; SENSE, sensitivity encoding; TE, echo time; TFE, turbo
, T1-weighted modified volumetric isotropic TSE acquisition; T1-mVISTA_1.0,
3D, 3-dimensional.
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provided for decision making of an enhancing lesion. The reader was
blinded regarding the clinical outcome, advised to mark every
contrast-enhancing MS suspect lesion and to assess the visual contrast
enhancement (VCE; 0 = no; 1 = slight; 2 = moderate; 3 = strong con-
trast enhancement) and the diagnostic confidence (DC; probability of
contrast-enhancing MS lesion is: 1 = unlikely; 2 = vague; 3 = likely;
4 = high; 5 = very high). Furthermore, the reader had to assess the im-
age quality of T1-mVISTA and MP-RAGE sequences as follows:
1 = poor, diagnosis strongly impaired; 2 = adequate, major artifacts;
3 = good, only minor artifacts; and 4 = excellent, no artifacts.
A second reader, who was aware of the reference lesions,
rereviewed the marked lesions from the first reader and transferred
the results to an Excel sheet. Subsequently, the second reader per-
formed a side-to-side comparison for determination of the CNR and
for size measurements of the lesions. For CNR measurements, regions
of interest (ROIs) were placed in the center of the maximum signal in-
tensity (SI) of each lesion and the adjacent brain parenchyma in a side-
to-side comparison with the same area of ROI in each sequence.




The μwas the average SI of the ROI, and SDwas the standard deviation
of noise of the respective region. Because noise distribution was inho-
mogeneous due to parallel imaging techniques28 and visibility of le-
sions is dependent on the surrounding contrast, the SI and SD for the
calculation of CNR were taken from the adjacent white matter.
For the determination of lesion size, the maximum length of the
lesion in either axial, sagittal, or coronar reformation was measured in
both sequences in a side-to-side comparison. Moreover, according to
the MAGNIMS consensus guidelines, lesion location was recorded as
periventricular, cortical/juxtacortical, or infratentorial, respectively.2
All images were analyzed on a picture archiving and communi-
cation system (Syngo; Siemens AG Healthcare, Erlangen, Germany).
Statistical Analysis
Weperformed all statistical analyses using SPSS 23 (IBM,Armonk,
NY). Metric and normally distributed variables are reported as mean ± SD;
nonnormally distributed variables are presented as median with first to
third quartiles. Categorical variables are presented as frequency and
percentage. The 2-sample t test was used for lesion size in MP-RAGE.
The VCE, CNR, number of lesions, localization, and size in
T1-mVISTA and T1-mVISTA_1.0 did not display normal distributions;
the Wilcoxon test was used for paired samples, and the Mann-Whitney
U test was used for unpaired samples. Fisher exact test was applied
for the detection of differences in localizations of lesions between le-
sions detected and lesions missed in MP-RAGE.
Two-sided P values were determined, and values below 0.05
were considered significant.TABLE 2. Comparison of Lesions Detected Both in MP-RAGE and
VISTA, Both With 0.8 mm Isotropic Resolution
n MP-RAGE T1-mVISTA P
Size, mm 39 5 (3–7) 5 (4–8) <0.001*
VCE 39 2.0 (1.0–2.0) 3.0 (3.0–3.0) <0.001*
CNR 39 14.6 (7.9–24.3) 29.7 (17.7–45.0) <0.001*
DC 39 5 (3–5) 5 (5–5) <0.001*
*Wilcoxon test.
CNR indicates contrast-to-noise ratio; DC, diagnostic confidence on a 5-point
Likert scale; VCE, visual contrast enhancement on a 3-point Likert scale;MP-RAGE,
magnetization-prepared rapid gradient echo; T1-mVISTA, T1-weighted modified
volumetric isotropic TSE acquisition.RESULTS
Patient Cohort
A total of 22 patients (8 male [36.4%]; age, 31.0 ± 9.2) was
included in the study. All patients received a protocol with T1-mVISTA
and MP-RAGE; a subgroup of 12 patients additionally received a
T1-mVISTA_1.0. Half of the patients (11 of 22) displayed contrast-
enhancing lesions. Among the 11 patients with contrast-enhancing
lesions, 6 received the T1-mVISTA as the first sequence, whereas
5 received the MP-RAGE as the first sequence. Among patients
with missed lesions, there was no signif icant difference on the
order of the sequences (P > 0.05). In the substudy for comparison of© 2017 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2017 Wolters Kluwer HT1-mVISTA and T1-mVISTA_1.0, 7 of 12 patients showed contrast-
enhancing lesions.
MP-RAGE vs T1-mVISTA
When comparing T1-mVISTA and MP-RAGE, 39 lesions were
detected with both sequences. The VCE, CNR, and DC were rated
significantly higher for T1-mVISTA compared with MP-RAGE (all
P < 0.001; Table 2; Fig. 1). Lesions detected by T1-mVISTA appeared
significantly bigger than lesions detected by MP-RAGE (P < 0.001;
Table 2). There was no significant difference regarding the image
quality for either sequence on a 4-point Likert scale (T1-mVISTA
[4–4] vs MP-RAGE [3.75–4], P = 0.705).
Total Number of Lesions
Overall, significantly more lesions were detected with T1-mVISTA
compared with MP-RAGE (71 vs 39; P < 0.001; Fig. 1). Lesions de-
tected only by T1-mVISTA (n = 32) were significantly smaller com-
pared with lesions seen in both sequences (3.0 mm [2.0–6.0 mm] vs
5.0 mm [4.0–8.0 mm], P = 0.002). The VCE and CNR were rated sig-
nificantly lower for lesions detected only by T1-mVISTA (P < 0.001;
Table 3). Although the DC for lesions only displayed by T1-mVISTA
turned out to be significantly lower (P < 0.001), median DC was rated
with 5.0 (4.0–5.0) on a 5-point Likert scale. No lesion was detected ex-
clusively in MP-RAGE but overseen in T1-mVISTA.
Although failing to be significant, lesions only detected by
T1-mVISTA tended to be localized more often in the juxtacortical area,
whereas lesions detected with both sequences were more often local-
ized in the periventricular area (62.5% vs 48.7%).
Moreover, in 2 cases, we detected contrast enhancement of
the optic nerve in patients with clinically apparent optic neuritis as
secondary finding.
Missed Lesions in MP-RAGE and T1-mVISTA on First
Review Compared With Corresponding
Reference Lesions
Ten of 39 reference lesions (25.6%) were missed in MP-RAGE
sequences in the initial reading, whereas only 3 of 71 reference lesions
(4.2%) were missed in T1-mVISTA (Fig. 2). The 10 lesions missed in
MP-RAGE were significantly smaller compared with the lesions that
were not overseen (3.0 mm [2.0–4.0 mm] vs 6.0 mm [3.5–9.0 mm];
P = 0.003). However, there was no significant difference regarding
the VCE and CNR of the 10 lesions missed compared with the VCE
and CNR of the lesions detected (P = 0.52 and P = 0.62, respectively).
T1-mVISTA vs T1-mVISTA_1.0
When comparing T1-mVISTA and T1-mVISTA_1.0 in a substudy
for analysis of decreased acquisition time (1:55 vs 4:43minutes), all lesions
detected by T1-mVISTAwere also seen in T1-mVISTA_1.0 (n = 40).www.investigativeradiology.com 15
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TABLE 3. Comparison of Lesions Detected Only in T1-mVISTA
(n = 32) vs Lesions Seen in MP-RAGE, Both With 0.8 mm Isotropic
Resolution
Sommer et al Investigative Radiology • Volume 53, Number 1, January 2018No significant differences were detected regarding VCE, CNR, DC, and
lesion size (Table 4; Fig. 3). However, image quality was rated to be
significantly lower in T1-mVISTA_1.0 compared with T1-mVISTA onFIGURE 1. Scans in axial reconstruction of 2 different patients are
displayed in this figure: T2 FLAIR (C and H), precontrast MP-RAGE
(A and F), precontrast T1-mVISTA (B andG), contrast-enhancedMP-RAGE
(D and I), and contrast-enhanced T1-mVISTA (E and J). All scans were
acquired at 0.8 mm isotropic resolution. After contrast agent application,
T1-mVISTA was acquired before MP-RAGE in patient 1 and vice versa in
patient 2. In patient 1, 2 contrast-enhancing lesions are displayed: 1 lesion
in the white matter of the right temporal lobe adjacent to the temporal
horn and another lesion in the left temporal lobe in cortical/juxtacortical
localization. Both lesions appear hypointense in precontrast MP-RAGE
and hypointense to cortex isointense in precontrast T1-mVISTA. Both
lesions display a contrast enhancement; however, the signal intensities
of lesions displayed by T1-mVISTA are increased and lesions appear
brighter compared with the MP-RAGE sequence. Especially, the lesion
in the cortical/juxtacortical localization displays a low contrast compared
with the adjacent white matter. In patient 2, an annular-enhancing
lesion is seen in the left periventricular white matter both in
contrast-enhanced MP-RAGE (I) and in contrast-enhanced T1-mVISTA
(J). However, 2 additional lesions can be clearly depicted in the white
matter of the right posterior and the left frontal lobe in
contrast-enhanced T1-mVISTA (J), whereas at best faint and no contrast
agent uptake is seen in the corresponding MP-RAGE (I), respectively.
MP-RAGE indicates magnetization-prepared rapid gradient echo;
T1-mVISTA, T1-weightedmodified volumetric isotropic TSE acquisition;
T2 FLAIR, T2-weighted fluid attenuation inversion recovery.
Detected Lesions in
MP-RAGE (n = 39)
Lesions Seen Only in
T1-mVISTA (n = 32) P
Size,* mm 5.0 (4.0–8.0) 3.0 (2.0–6.0) 0.002†
VCE* 3.0 (3.0–3.0) 2.0 (2.0–2.0) <0.001†
CNR* 29.7 (17.3–45.0) 17.5 (11.8–24.6) <0.001†
DC* 5.0 (5.0–5.0) 5.0 (4.0–5.0) <0.001†
*As measured in VISTA 0.8. †Mann-Whitney U test.
CNR indicates contrast-to-noise ratio; DC, diagnostic confidence on a 5-point
Likert scale; VCE, visual contrast enhancement on a 3-point Likert scale;
MP-RAGE, magnetization-prepared rapid gradient echo; T1-mVISTA, T1-weighted
modified volumetric isotropic TSE acquisition.
16 www.investigativeradiology.com
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voxel size (3.0 [3.0–3.0] vs 4.0 [3.0–4.0], respectively; P < 0.05).
DISCUSSION
The results of this single-center study show that 3D T1-mVISTA
improves the detectability of contrast-enhancing cerebral MS lesions by
almost doubling the detection rate (54.9%) due to increasing the CNR
of the lesions significantly. Further, significantly fewer lesions were
missed in T1-mVISTA compared with the standardMP-RAGE sequence
(4.2 vs 25.6%, respectively).
Because 2 or more contrast-enhancing lesions have reported to
be associated with a worse clinical outcome and therapeutic aims
have shifted to no evident disease activity, which is defined by clin-
ical and MRI parameters,14 the total number of active lesions is of high
clinical relevance.
When comparing postcontrast MP-RAGE and T1-mVISTA, we
noticed differences in contrast agent behavior: there were some T2
FLAIR hyperintense lesions, which were enhancing on T1-mVISTA but
seemed hypointense on contrast-enhanced MP-RAGE. On the corre-
sponding non–contrast-enhanced T1-mVISTA, these lesions were ei-
ther slightly hypointense or isointense to the white matter.
Nonenhancing T1 hypointense lesions, in the literature also known
as black holes, were reported to be areas of edema or chronic lesions
representing severe axonal damage.29–31 Black holes begin as a contrast-
enhancing lesion and evolve differently over time: they can shrink,
enlarge, or become permanent.32 Acute black holes display contrast en-
hancement, whereas persistent black holes lose contrast agent uptake.30,32
These permanent black holes were observed to be associated with a
worse long-term outcome and disease progression.33,34 Bagnato et al32
showed in their monthly follow-up of 9 untreated RRMS patients over
4 years that 55.7% of acute black holes developed into persisting black
holes and that the likeliness of the formation of a persisting black hole
correlated with the duration of contrast enhancement. Our results sug-
gest that residual contrast enhancement of black holes, as defined by
Bagnato et al, can be detected with T1-mVISTA due to the increased
CNR, whereas this can partially be masked in MPRAGE sequences.
Because duration of contrast enhancement seems to be a key factor in
pathogenesis of RRMS and long-term outcome, further studies are needed
to investigate the consequence of the additional contrast-enhancing le-
sions displayed by T1-mVISTA.
In general, lesions appeared bigger in the T1-mVISTA images, a
phenomenon we already encountered in our previous study on brain
metastases.25 Kato et al20 also described that finding when comparing
T1-SPACE and MP-RAGE in brain metastases, a congeneric sequence
to T1-mVISTA. In accordance to Kato et al, we also assume that the in-
crease of CNR might have lead to an increase in lesion size.© 2017 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
FIGURE 2. The figure displays examples ofmissed lesions by contrast-enhancedMP-RAGE in 2 different patients (A and B). The first lesion in patient Awas
located in the white matter of the right posterior lobe adjacent to the cortex; the second lesion and third lesion in patient B were located in
cortical/juxtacortical localization in the left mesial temporal lobe and in the white matter of the left posterior lobe, respectively. All lesions were missed in
contrast-enhanced MP-RAGE due to the lower contrast-to-noise ratio compared with T1-mVISTA. In both patients, T1-mVISTA was acquired before
MP-RAGE. CE indicates contrast-enhanced; MP-RAGE, magnetization-prepared rapid gradient echo; T1-mVISTA, T1-weighted modified volumetric
isotropic TSE acquisition; T2 FLAIR, T2-weighted fluid attenuation inversion recovery.
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MP-RAGE compared with T1-mVISTA: with 3D MP-RAGE, 25.6%
(10/39) of the reference lesions were missed in the initial reading,
whereas only 4.2% (3/71) of the reference lesions were missed with
T1-mVISTA. This finding is consistent with a study of Reichert et al35
on brain metastases; the authors also reported that lesion detection was
significantly improved when using T1-SPACE (99.1% of lesions for
reader 1 and 96.3% of lesions for reader 2) compared with MP-RAGE
(73.6% of lesions for reader 1 and 68.5% of lesions for reader 2).
The reasons for the impaired lesion detection with MP-RAGE
are probably the combination of the decreased CNR of the contrast-
enhancing lesion to the adjacent parenchyma and the increase of
CNR between white and gray matter as displayed in Figure 2 and al-
ready observed in our study comparing T1-mVISTA and MP-RAGE
in patients with brain metastases.25Moreover, because contrast between
gray and white matter is decreased25 as well as the signal of blood vessels
is suppressed, T1-mVISTA creates a more homogeneous image back-
ground without distracting signals from enhanced vessels, such as in
MP-RAGE.20 Therefore, small, low contrast-enhancing lesions are
not masked in T1-mVISTA compared with MP-RAGE.
Moreover, significantly more lesionswere detected by T1-mVISTA
compared with MP-RAGE (71 vs 39 lesions, 54.9%). Lesions only de-
tected by T1-mVISTAwere significantly smaller (<5 mm). Although the
VCE and CNR of smaller lesions detected only by T1-mVISTA wereTABLE 4. Comparison of Lesions Detected in T1-mVISTA_1.0
(1.0 mm3 resolution) and T1-mVISTA (0.8 mm3 Resolution)
n T1-mVISTA_1.0 T1-mVISTA P
Size, mm 40 5.5 (3.0–7.75) 5.5 (3.0–7.0) 1.0*
VCE 40 2.0 (2.0–3.0) 2.0 (2.0–3.0) 0.083*
CNR 40 18.4 (11.5–32.8) 18.2 (13.1–28.1) 0.677*
DC 40 5.0 (4.0–5.0) 5.0 (4.0–5.0) 0.157*
*Wilcoxon test.
CNR indicates contrast-to-noise ratio; DC, diagnostic confidence on a 5-point
Likert scale; VCE, visual contrast enhancement on a 3-point Likert scale;
MP-RAGE, magnetization-prepared rapid gradient echo; T1-mVISTA, T1-weighted
modified volumetric isotropic TSE acquisition.
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2017 Wolters Kluwer Hsignificantly decreased, DC was still high, with a median of 5 on a
5-point scale compared with lesions detected in both sequences.FIGURE 3. The left vertical row shows contrast-enhanced T1-mVISTA
at 0.8 mm isotropic resolution (T1-mVISTA), the right vertical row
displays contrast-enhanced T1-mVISTA at 1.0 mm isotropic resolution
(T1-mVISTA_1.0) of 2 different patients (A and B). In general, all 3
contrast-enhancing lesions are depicted with comparable signal
intensities by T1-mVISTA and T1-mVISTA_1.0, respectively. However,
due to the lower resolution, the image quality of T1-mVISTA_1.0 is slightly
impaired because the margins of the lesions, the vessel contours, and
the general image impression seem a little more blurred. In both patients,
T1-mVISTA_1.0 was acquired before T1-mVISTA. T1-mVISTA indicates
T1-weighted modified volumetric isotropic TSE acquisition.
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Sommer et al Investigative Radiology • Volume 53, Number 1, January 2018The increase of detected contrast-enhancingMS lesions is in line
with a previous study of Hodel et al36; the authors detected 40.6%more
contrast-enhancing lesions (90 vs 64) in 19 MS patients using a 3D
T1w TSE sequence (Brain View; Philips, a congeneric sequence to
T1-mVISTA) in 4-mm-thick axial reformats compared with a standard
2D T1w SE sequence with 4-mm slice thickness and even 65.5% more
lesions (106 vs 64) when using multiplanar reconstructions with 1.2-mm
resolution.36 They also reported a significantly higher contrast rate for
the 3D T1w TSE than for the 2D SE sequence.
In a previously published study of our group on the detection of
brain metastases, we reported an increased detection rate of 59.0% for
contrast-enhancing metastases (61 vs 36) and a significantly increased
CNR comparing 3D T1-mVISTA to conventional 3D MP-RAGE.25 Two
other studies using 3D BB T1w TSE sequences also reported higher de-
tection rates for brain metastasis, especially for small lesions < 5mm.19,20
Compared with the commercially available sequence used by
Hodel et al36 and the studies on brain metastases of Kato et al20 and
Park et al,19 scan times of our protocol were considerably shorter at
comparable image resolutions (1.0 mm isotropic) without impairment
of lesion detectability and image quality (1:55 vs 4:42 minutes in the
study by Kato et al, 5:30 minutes in the study by Hodel et al, and
9:00 minutes in the study by Park et al).
The reasons for the higher detectability with T1-mVISTAwere
probably multifactorial. First, in conventional 3D T1w TSE BB se-
quences, after an initial decrease, the refocusing angle reaches a plateau,
which results in a fast signal loss. The refocusing angle in T1-mVISTA
continually increases afterward, resulting in a slower signal loss.25 The
use of a long echo train in T1-mVISTA compared with other stud-
ies19,20,36 might further contributes to scan efficiency and allows for a
high resolution in a shorter scan time. Moreover, the entire k-space is
used in T1-mVISTA, therefore, no information regarding image con-
trast and image sharpness is lost.25
Although not investigated in this study, our initial experience
demonstrates that the orbital cavity could also be assessed with high-
resolution, fat-saturated T1-mVISTA, with the same sequence to
diagnose or exclude optic neuritis, a common primary symptom
in MS patients and recently recommended to be included to the
McDonald criteria in the consensus paper of the European collab-
orative for MR studies in MS of 2016.2 Therefore, application of
T1-mVISTA could be timesaving in the clinical routine, as a conven-
tional 2D T1w SE sequence in axial and coronal slicing would result
in longer scan times.
There are several limitations in our study. First, the small number
of patients is a substantial limitation of our study. As only 11 of
22 patients displayed contrast-enhancing lesions, our results can only
be interpreted as an indication for a superiority of T1-mVISTA. Second,
blinding to sequence type was not possible due to the characteristic ap-
pearance of T1-mVISTA. Third, we did not compare T1-mVISTA to
2D T1w SE sequences. However, Hodel et al36 had already showed that
3D T1w TSE was superior in the detection of contrast-enhancing le-
sions and displayed less pulsation artifacts compared with 2D T1w
SE sequence. Moreover, we did not compare T1-mVISTA to a spoiled
gradient recalled echo sequence, which might have performed better
than MP-RAGE. Because it is not used in our clinical routine, we did
not apply subtraction techniques, which could have probably led to
an increase of detection rate in contrast-enhanced MP-RAGE as re-
ported by Dodo et al37 in a comparison of contrast-enhanced
MP-RAGE and 2D SE in patients with glioma. Further, we only mea-
sured the length of the lesions, but not the volume, which would have
been more precise.
In a future study, we aim to explore, whether the increase of
CNR in T1-mVISTA can be used to reduce the gadolinium dose, as re-
duction of gadolinium dose is of utmost clinical importance to keep the
chance of gadolinium deposition as low as possible, especially in pa-
tients with MS due to patients' age and the repetitive MRI scans.18 www.investigativeradiology.com
Copyright © 2017 Wolters Kluwer HMoreover, the combination of a gadolinium decreased protocol
with a 32-channel head coil might lead to a further increase of the detec-
tion rate and a decrease in scan time.
In conclusion, our findings suggest that 3D T1-mVISTA seems
to be superior to conventional 3D MP-RAGE for the detection of
contrast-enhancing cerebral lesions inMS patients. Higher detectability
of active lesions might improve the early diagnosis of MS, the diagnostic
performance and might, therefore, be supportive in future studies and ther-
apeutic management ofMS patients. However, further studies with a larger
patient cohort should be performed to confirm these initial findings.
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